License and Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Three months ended June 30,				Six months ended June 30,
Partner	Drug or Drug Candidate	2019		2018		2019	2018
Bristol-Myers Squibb	NKTR-214	—		1,059,768		—	1,059,768
Eli Lilly and Company	NKTR-358	1,200		3,052		3,700	5,406
Baxalta Incorporated/Takeda	ADYNOVATE®	58		18		78	10,028
Amgen, Inc.	Neulasta®	1,250		1,250		2,500	2,500
Other		27		158		461	271
License, collaboration and other revenue		$	2,535	$	1,064,246	6,739	$	1,077,973

Changes in Deferred Revenue Balance from Collaboration Agreements

The following table presents the changes in our deferred revenue balance from our collaboration agreements during the six months ended June 30, 2019 (in thousands):

	Six months ended June 30, 2019
Deferred revenue—December 31, 2018	$	24,636
Recognition of previously unearned revenue	(6,715		)
Deferred revenue—June 30, 2019	$	17,921